SCHEMBL9539346

SCHEMBL9539346

COC(=O)Oc1nnc(O)c2[nH]cnc12

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.32
CSNK2A2 P19784 1/20 0.32
RAB9A P51151 1/20 0.32
CSNK2B P67870 1/20 0.32
CSNK2A1 P68400 1/20 0.32
KMT2A Q03164 1/20 0.32
DYRK1A Q13627 1/20 0.32
CSNK2A3 Q8NEV1 1/20 0.32
GDA Q9Y2T3 1/20 0.31
PDPK1 O15530 2/20 0.31
MKNK1 Q9BUB5 1/20 0.30
HPGD P15428 1/20 0.30
MGMT P16455 1/20 0.30
ABL1 P00519 1/20 0.30
RAD52 P43351 1/20 0.30
RIN1 Q13671 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9542967 0.89 CSNK2A2 (0.34) MEN1CSNK2A2RAB9ACSNK2BCSNK2A1
SCHEMBL9541784 0.88 MEN1 (0.32) MEN1CSNK2A2RAB9ACSNK2BCSNK2A1
SCHEMBL9539357 0.87 KDM4E (0.34) HPGD
SCHEMBL9542989 0.85 ELANE (0.34)
SCHEMBL9540477 0.85 KDM4E (0.38) MEN1RAB9AKMT2APDPK1HPGD
SCHEMBL9540456 0.82 ALOX5 (0.36) RAB9AHPGDMGMT
SCHEMBL9540433 0.80 LMNA (0.43) RAB9AHPGD
SCHEMBL9543043 0.79 ALDH1A1 (0.38) HPGD
SCHEMBL9539338 0.77 CDC7 (0.40) MEN1KMT2AMGMT
SCHEMBL9540355 0.76 KDM4E (0.32) HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1993003033-A1 CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G. D. SEARLE & CO. (US) 1993-02-18 WO claimed
WO-1993003033-A1 CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G. D. SEARLE & CO. (US) 1993-02-18 WO disclosed